OPDUALAG
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OPDUALAG (OPDUALAG).
Nivolumab is a human IgG4 monoclonal antibody that binds to PD-1 on activated T-cells, blocking interaction with its ligands PD-L1 and PD-L2, thereby restoring anti-tumor T-cell function.
| Metabolism | Nivolumab is a monoclonal antibody degraded into small peptides and amino acids via general protein catabolism; not metabolized by CYP450 enzymes. |
| Excretion | Primarily eliminated via biliary/fecal route (approximately 80%) and renal excretion accounts for less than 20% as unchanged drug and metabolites. |
| Half-life | Terminal elimination half-life is approximately 23-27 days, allowing for every-4-week dosing intervals. |
| Protein binding | Approximately 70-80% bound to plasma proteins, primarily to albumin. |
| Volume of Distribution | Volume of distribution is approximately 6-7 L, indicating limited extravascular distribution and primarily residing in the vascular space. |
| Bioavailability | Intravenous administration yields 100% bioavailability; no other routes are clinically relevant. |
| Onset of Action | Intravenous administration: onset of clinical effect observed within 2-4 weeks based on tumor response assessments. |
| Duration of Action | Duration of action is prolonged, with sustained receptor occupancy for several weeks after a single dose; clinical effects persist through the dosing interval (4 weeks). |
For patients with relapsed or refractory classical Hodgkin lymphoma: 2.7 mg/kg (up to 200 mg) intravenously over 60 minutes every 3 weeks until disease progression or unacceptable toxicity.
| Dosage form | SOLUTION |
| Renal impairment | No formal renal adjustment guidelines. Use caution in severe renal impairment (CrCl <30 mL/min) due to limited data. |
| Liver impairment | Child-Pugh Class A: No adjustment; Class B: Reduce dose to 1.8 mg/kg (up to 135 mg) every 3 weeks; Class C: Not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients. No specific dosing recommendations available. |
| Geriatric use | No specific dose adjustment required; monitor renal function and overall tolerance due to potential age-related organ function decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OPDUALAG (OPDUALAG).
| Breastfeeding | No data on presence in human milk or effects on breastfed infant. Given the large molecular weight of monoclonal antibodies, excretion into breast milk is likely low, but systemic absorption in the infant is possible. M/P ratio not known. Use during breastfeeding is not recommended due to potential for immune suppression or adverse effects in the infant. Consider discontinuing breastfeeding or the drug. |
| Teratogenic Risk | Opdualag (nivolumab + relatlimab) is an immune checkpoint inhibitor. Based on its mechanism of action (PD-1 and LAG-3 blockade), it can cause fetal harm. In animal studies, inhibition of PD-1 and LAG-3 pathways has been associated with increased risk of immune-mediated rejection of the developing fetus, potentially leading to fetal death or developmental abnormalities. Use is contraindicated in pregnancy unless the benefit outweighs the risk. First trimester: potential for miscarriage or malformation; second and third trimesters: risk of immune-mediated fetal injury. |
■ FDA Black Box Warning
Immune-mediated adverse reactions: including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and dermatologic reactions. Fatal and serious toxicities can occur. Monitor closely and manage with treatment interruption, corticosteroids, or discontinuation as indicated.
| Serious Effects |
None known beyond hypersensitivity to nivolumab or any excipients.
| Precautions | Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies (hypophysitis, adrenal insufficiency, hypothyroidism, thyroiditis, type 1 diabetes), nephritis, dermatologic reactions, infusion-related reactions, embryo-fetal toxicity, and complications of allogeneic HSCT. Monitor liver function, renal function, thyroid function, and for signs of colitis. |
Loading safety data…
| Fetal Monitoring | Monitor maternal thyroid function, liver function, renal function, and complete blood count regularly during treatment. Assess for immune-related adverse events (e.g., pneumonitis, colitis, hepatitis, endocrinopathies) that could affect pregnancy. Fetal monitoring includes ultrasound for growth restriction and assessment for hydrops fetalis if immune-mediated hemolysis occurs. No specific fetal heart rate monitoring required unless complications arise. |
| Fertility Effects | No formal studies on fertility. Based on animal models, immune checkpoint inhibitors may impair female fertility by altering immune tolerance during implantation and early pregnancy. In males, no known direct effect on spermatogenesis, but chronic immune activation could theoretically affect reproductive function. Advise patients of potential reduced fertility. |